Muscarinic M1 agonist as an inhibitor of beta-amyloid (Abeta40 and Abeta42)-synthesis

摘要

Methods of lowering the levels of Abeta40, Abeta42 and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine, or a physiologically acceptable acid addition salt thereof, and methods of treating diseases associated with the formation of diffuse and senile plaques or Abeta40-, Abeta42- and tau-containing plaques are disclosed.